Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TroFuse-011: MK-2870 ± Keytruda vs Treatment of Physician's Choice in First-line PD-L1–low TNBC
jRCT2031250059Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan in triple-negative breast cancer (TNBC) (3 arms), sponsored by Merck & Co. Primary endpoints: Progression-free survival (MK-2870 vs TPC), Progression-free survival (MK-2870 + MK-3475 vs TPC) and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on jRCT2031250059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250059.